MEK inhibitor PD-0325901 and rapamycin combined treatment effect on malignant peripheral nerve sheath tumor model
Summary:
Analysis of malignant peripheral nerve sheath tumors (MPNST) from NPcis animals (carrying Nf1 and p53 mutations) treated with rapamycin, MEK inhibitor PD-0325901, or the combination of rapamycin and PD-0325901. Results provide insight into the molecular mechanisms underlying MPNST pathogenesis.
Malone CF, Fromm JA, Maertens O, DeRaedt T et al. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov 2014 Sep;4(9):1062-73. PMID: 24913553
